Equities Analysts Set Expectations for Genomic Health, Inc.’s FY2017 Earnings (GHDX)

Genomic Health, Inc. (NASDAQ:GHDX) – Investment analysts at William Blair dropped their FY2017 earnings estimates for shares of Genomic Health in a report released on Monday. William Blair analyst A. Murphy now anticipates that the medical research company will earn ($0.09) per share for the year, down from their prior forecast of $0.01. William Blair also issued estimates for Genomic Health’s FY2019 earnings at $0.65 EPS.

GHDX has been the topic of several other reports. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, October 13th. Cowen and Company reissued a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a report on Friday, September 1st. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a report on Thursday, September 14th. Canaccord Genuity reissued a “buy” rating and issued a $39.00 price target on shares of Genomic Health in a report on Wednesday. Finally, BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $32.67.

ILLEGAL ACTIVITY WARNING: This article was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://transcriptdaily.com/2017/11/17/equities-analysts-set-expectations-for-genomic-health-inc-s-fy2017-earnings-ghdx.html.

Genomic Health (NASDAQ GHDX) opened at $29.04 on Wednesday. Genomic Health has a fifty-two week low of $26.37 and a fifty-two week high of $34.02.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Genomic Health during the 3rd quarter worth approximately $138,000. Point72 Asset Management L.P. acquired a new stake in shares of Genomic Health during the 3rd quarter worth approximately $350,000. Jane Street Group LLC acquired a new stake in shares of Genomic Health during the 3rd quarter worth approximately $227,000. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Genomic Health by 22.5% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 16,337 shares of the medical research company’s stock worth $524,000 after acquiring an additional 3,000 shares in the last quarter. Finally, University of Notre Dame DU Lac boosted its position in shares of Genomic Health by 3.0% during the 3rd quarter. University of Notre Dame DU Lac now owns 82,503 shares of the medical research company’s stock worth $2,648,000 after acquiring an additional 2,368 shares in the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.

In related news, insider James J. Vaughn sold 1,379 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Kimberly J. Popovits sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. Insiders have sold 21,379 shares of company stock worth $676,131 over the last ninety days. Insiders own 46.20% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply